These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34467833)

  • 1. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Hsu A; Kurt H; Zayac AS; Olszewski AJ
    Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
    Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
    Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
    Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
    Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
    Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
    Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
    Liu Z; Markham M; Mandernach MW
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma].
    Koike T; Iriyama N; Nakagawa M; Takahashi H; Hamada T; Uchino Y; Miura K; Hatta Y; Nakayama T; Takei M
    Rinsho Ketsueki; 2020; 61(3):245-250. PubMed ID: 32224585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
    Cheah CY; Opat S; Trotman J; Marlton P
    Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.
    Bommier C; Donzel M; Rossi C; Fornecker LM; Bijou F; Chauchet A; Lebras L; Ysabaert L; Haioun C; Bouabdallah K; Gastinne T; Morineau N; Amorim S; Jardin F; Abraham J; Lamy de la Chapelle T; Gressin R; Fouillet L; Fruchart C; Olivier G; Morschhauser F; Cherblanc F; Belot A; Le Guyader S; Monnereau A; Ghesquieres H; Thieblemont C
    Hematol Oncol; 2024 Nov; 42(6):e3314. PubMed ID: 39351974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
    Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
    Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Iannitto E; Ferrero S; Bommier C; Drandi D; Ferrante M; Bouabdallah K; Carras S; Gini G; Camus V; Mancuso S; Marcheselli L; Ferrari A; Merli M; Tessoulin B; Stelitano C; Beldjord K; Roti G; Jardin F; Castagnari B; Palombi F; Baseggio L; Traverse-Glehen A; Tripodo C; Liberati AM; Parolini M; Usai S; Patti C; Federico M; Musso M; Ladetto M; Zucca E; Thieblemont C
    Haematologica; 2024 Jul; 109(7):2297-2302. PubMed ID: 38497158
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
    Carter SJ; Bernstein SH; Friedberg JW; Barr PM
    Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Cencini E; Fabbri A; Schiattone L; Bocchia M
    Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
    [No Abstract]   [Full Text] [Related]  

  • 19. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.
    Xia Y; Ge J; Sun Z; Nan F; Wan W; Xu D; Zhang M; Fu X
    Leuk Res; 2022 Jun; 117():106840. PubMed ID: 35468520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.